Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans

Abstract

1. The absorption, distribution, metabolism, and excretion of fasiglifam were investigated in rats, dogs, and humans.

2. The absolute oral bioavailability of fasiglifam was high in all species (>76.0%).

3. After oral administration of [¹⁴C]fasiglifam, the administered radioactivity was quantitatively recovered and the major route of excretion of radioactivity was via feces in all species.

4. Fasiglifam was a major component in the plasma and feces in all species. Its oxidative metabolite (M-I) was observed as a minor metabolite in rat and human plasma (<10% of plasma radioactivity). In human plasma, hydroxylated fasiglifam (T-1676427), the glucuronide of fasiglifam (fasiglifam-G), and the glucuronide of M-I were detected as additional minor metabolites (<2% of plasma radioactivity). None of these metabolites were specific to humans. Fasiglifam-G was the major component in the rat and dog bile.

5. In vitro cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) reaction phenotyping indicated that oxidation (to form M-I and T-1676427) and glucuronidation of fasiglifam are mainly mediated by CYP3A4/5 and UGT1A3, respectively.

6. Fasiglifam and fasiglifam-G are substrates of BCRP and Mrp2/MRP2, respectively.

7. Glucuronidation of fasiglifam-G was found to be the predominant elimination pathway of fasiglifam in all species tested, including humans.

Keywords:

• TAK-875
• fasiglifam
• G protein-coupled receptor 40
• disposition
• metabolite profiling
• pharmacokinetics
• LC/MS

Disclosure statement

All studies reported here were supported and conducted by Takeda Pharmaceutical Company Limited. The authors declare no other conflicts of interest.